🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05010863
Recruiting Observational

Gastric Cancer Marker Detection and Its Kit Development

NCT05010863 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Phase
Observational
Started
2021-01-01
Last updated
2021-08-18

Condition(s) studied

Gastric Cancer

Investigational drug(s) / intervention(s)

Blood collection

Blood collection: The subject will be drawn a 5ml blood sample

Study summary

The gastric cancer diagnosis and treatment specifications clearly point out that tumor markers need to be detected in the process of diagnosis, efficacy evaluation and follow-up. However, there is currently a lack of gastric cancer markers with high sensitivity and specificity, and the detection of markers is limited to a single index analysis, which has many shortcomings such as long analysis time, large reagent consumption, and high detection cost. Therefore, this project will use protein chips to detect new types of gastric cancer patient markers and establish a multi-diagnostic model for early screening of gastric cancer. Finally, monoclonal antibodies will be produced against various high-specific tumor markers and a gastric cancer diagnostic kit will be established.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
Accepted
Inclusion Criteria: patient 1. Age is greater than or equal to 18 years old (including 18 years old); 2. Patients who are diagnosed with cancer after pathological diagnosis; 3. Can provide enough tissue samples; 4. Have not received anti-tumor treatment in the past; 5. Comply with the principle of informed consent and sign the informed consent form. healthy person: 1. Age is greater than or equal to 18 years old (including 18 years old); 2. No underlying disease; 3. Can provide enough tissue samples; 4. Comply with the principle of informed consent and sign the informed consent form. Exclusion Criteria: 1. The tumor foci cannot be clearly derived from a specific tumor type; 2. Those who have a history of other tumors, autoimmune diseases and allergies; 3. Previously received anti-tumor treatments such as surgery, chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy, biological therapy or Chinese medicines with anti-cancer and anti-tumor effects in the instructions; 4. Participated in any clinical trial within 90 days before the experiment; 5. Received major surgery within 90 days before the experiment; 6. Received bone marrow transplantation 90 days before the experiment; 7. Subjects who may not be able to complete the study due to other reasons or who are determined by the investigator to be unsuitable to participate in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
No. 109, Xueyuan West Road, Lucheng District, Wenzhou City,Zhejiang provincece Wenzhou Zhejiang Recruiting

More Second Affiliated Hospital of Wenzhou Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05010863 on ClinicalTrials.gov ↗ ← All trials in China